PET and MR Imaging of Brain Tumors

PET Clinics

Volumn 3, Issue 3, 2008, Pages 293-315

  Goldberg, Michael F ^a   Chawla, Sanjeev ^a   Alavi, Abass ^a   Torigian, Drew A ^a   Melhem, Elias R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain tumor; Computed tomography; Magnetic resonance imaging; Neoplasm; PET CT; PET MR Imaging; Positron emission tomography; Single photon emission computed tomography

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 3 DEOXY 3 FLUOROTHYMIDINE F 18; 3 IODOMETIROSINE I 123; 3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; METHYLCHOLINE C 11; METHYLMETHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BRAIN TUMOR; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; DRUG HALF LIFE; DRUG METABOLISM; GLIOMA; GLUCOSE TRANSPORT; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE DISPLAY; ISOTOPE LABELING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BIOPSY; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

EID: 67249135365     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.02.001     Document Type: Review

References (137)

1. Smirniotopoulos J.G. The new WHO classification of brain tumors. Neuroimaging Clin N Am 9 4 (1999) 595-613
2. Kleihues P., Soylemezoglu F., Schauble B., et al. Histopathology, classification, and grading of gliomas. Glia 15 3 (1995) 211-221
3. Louis D.N., Holland E.C., and Cairncross J.G. Glioma classification: a molecular reappraisal. Am J Pathol 159 3 (2001) 779-786
4. Furnari F.B., Huang H.J., and Cavenee W.K. Genetics and malignant progression of human brain tumours. Cancer Surv 25 (1995) 233-275
5. Ichimura K., Bolin M.B., Goike H.M., et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60 2 (2000) 417-424
6. Jacobs A.H., Thomas A., Kracht L.W., et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 12 (2005) 1948-1958
7. Coleman R.E., Hoffman J.M., Hanson M.W., et al. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 32 4 (1991) 616-622
8. Herholz K., Wienhard K., and Heiss W.D. Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2 3 (1990) 240-265
9. Price P. PET as a potential tool for imaging molecular mechanisms of oncology in man. Trends Mol Med 7 10 (2001) 442-446
10. Jacobs A.H., Dittmar C., Winkeler A., et al. Molecular imaging of gliomas. Mol Imaging 1 4 (2002) 309-335
11. Utriainen M., Komu M., Vuorinen V., et al. Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS. J Neurooncol 62 3 (2003) 329-338
12. Tian M., Zhang H., Oriuchi N., et al. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 31 8 (2004) 1064-1072
13. Heiss W.D., Pawlik G., Herholz K., et al. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 4 2 (1984) 212-223
14. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41 4 (2000) 661-681
15. Kitajima K., Nakamoto Y., Okizuka H., et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 22 7 (2008) 595-602
16. Miwa K., Shinoda J., Yano H., et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatr 75 10 (2004) 1457-1462
17. Pirotte B., Goldman S., Dewitte O., et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 104 2 (2006) 238-253
18. Pichler B.J., Judenhofer M.S., and Wehrl H.F. PET/MRI hybrid imaging: devices and initial results. Eur Radiol 18 6 (2008) 1077-1086
19. Judenhofer M.S., Wehrl H.F., Newport D.F., et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14 4 (2008) 459-465
20. Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 296 9 (1977) 486-492
21. Hatanaka M., Augl C., and Gilden R.V. Evidence for a functional change in the plasma membrane of murine sarcoma virus-infected mouse embryo cells. Transport and transport-associated phosphorylation of 14C-2-deoxy-D-glucose. J Biol Chem 245 4 (1970) 714-717
22. Gallagher B.M., Fowler J.S., Gutterson N.I., et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19 10 (1978) 1154-1161
23. Merrall N.W., Plevin R., and Gould G.W. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 5 6 (1993) 667-675
24. Nishioka T., Oda Y., Seino Y., et al. Distribution of the glucose transporters in human brain tumors. Cancer Res 52 14 (1992) 3972-3979
25. Floeth F.W., Pauleit D., Sabel M., et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 47 5 (2006) 776-782
26. Zhuang H., and Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32 1 (2002) 47-59
27. Kubota R., Yamada S., Kubota K., et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33 11 (1992) 1972-1980
28. Chakrabarti R., Jung C.Y., Lee T.P., et al. Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. J Immunol 152 6 (1994) 2660-2668
29. Gamelli R.L., Liu H., He L.K., et al. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 59 5 (1996) 639-647
30. Sorbara L.R., Maldarelli F., Chamoun G., et al. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. J Virol 70 10 (1996) 7275-7279
31. Ahmed N., Kansara M., and Berridge M.V. Acute regulation of glucose transport in a monocyte-macrophage cell line: Glut-3 affinity for glucose is enhanced during the respiratory burst. Biochem J 327 Pt 2 (1997) 369-375
32. Janus T.J., Kim E.E., Tilbury R., et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33 5 (1993) 540-548
33. Spence A.M., Muzi M., Mankoff D.A., et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45 10 (2004) 1653-1659
34. Herholz K., Pietrzyk U., Voges J., et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79 6 (1993) 853-858
35. Hustinx R., Smith R.J., Benard F., et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET?. Eur J Nucl Med 26 11 (1999) 1501-1509
36. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 15 6 (2001) 471-486
37. Kim S., Chung J.K., Im S.H., et al. 11C-methionine PET as a prognostic marker in patients with glioma comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32 1 (2005) 52-59
38. Delbeke D., Meyerowitz C., Lapidus R.L., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195 1 (1995) 47-52
39. Kaschten B., Stevenaert A., Sadzot B., et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39 5 (1998) 778-785
40. Ogawa T., Inugami A., Hatazawa J., et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 17 2 (1996) 345-353
41. Tsuchida T., Takeuchi H., Okazawa H., et al. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol 35 2 (2008) 171-176
42. Herholz K., Rudolf J., and Heiss W.D. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 12 2 (1992) 159-165
43. Fischman A.J., and Alpert N.M. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 34 1 (1993) 6-11
44. Stockhammer F., Thomale U.W., Plotkin M., et al. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. J Neurosurg 106 4 (2007) 633-637
45. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22 5 (1987) 360-371
46. Alavi J.B., Alavi A., Chawluk J., et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62 6 (1988) 1074-1078
47. Kim C.K., Alavi J.B., Alavi A., et al. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 10 1 (1991) 85-91
48. Barker II F.G., Chang S.M., Valk P.E., et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79 1 (1997) 115-126
49. Padma M.V., Said S., Jacobs M., et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64 3 (2003) 227-237
50. Patronas N.J., Di Chiro G., Kufta C., et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62 6 (1985) 816-822
51. Tyler J.L., Diksic M., Villemure J.G., et al. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J Nucl Med 28 7 (1987) 1123-1133
52. Rozental J.M., Cohen J.D., Mehta M.P., et al. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 15 1 (1993) 57-66
53. Kosaka N., Tsuchida T., Uematsu H., et al. 18F-FDG PET of common enhancing malignant brain tumors. Am J Roentgenol 190 6 (2008) W365-W369
54. Kato T., Shinoda J., Nakayama N., et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. Am J Neuroradiol 29 6 (2008) 1176-1182
55. Cremerius U., Striepecke E., Henn W., et al. [18FDG-PET in intracranial meningiomas versus grading, proliferation index, cellular density and cytogenetic analysis]. Nuklearmedizin 33 4 (1994) 144-149
56. Henry J.M., Heffner Jr. R.R., Dillard S.H., et al. Primary malignant lymphomas of the central nervous system. Cancer 34 4 (1974) 1293-1302
57. Kracht L.W., Bauer A., Herholz K., et al. Positron emission tomography in a case of intracranial hemangiopericytoma. J Comput Assist Tomogr 23 3 (1999) 365-368
58. Kim E.E., Chung S.K., Haynie T.P., et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 12 2 (1992) 269-279
59. Wurker M., Herholz K., Voges J., et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 23 5 (1996) 583-586
60. Brock C.S., Young H., O'Reilly S.M., et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82 3 (2000) 608-615
61. Reinhardt M.J., Kubota K., Yamada S., et al. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med 38 2 (1997) 280-287
62. Yamamoto T., Nishizawa S., Maruyama I., et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 15 2 (2001) 103-109
63. De Witte O., Levivier M., Violon P., et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 39 3 (1996) 470-476 [discussion: 6-7]
64. Glantz M.J., Hoffman J.M., Coleman R.E., et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29 4 (1991) 347-355
65. Langleben D.D., and Segall G.M. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41 11 (2000) 1861-1867
66. Ricci P.E., Karis J.P., Heiserman J.E., et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. Am J Neuroradiol 19 3 (1998) 407-413
67. Henze M., Mohammed A., Schlemmer H.P., et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med 45 4 (2004) 579-586
68. Fulham M.J., Brunetti A., Aloj L., et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 83 4 (1995) 657-664
69. Wong T.Z., Turkington T.G., Hawk T.C., et al. PET and brain tumor image fusion. Cancer J 10 4 (2004) 234-242
70. Kahn D., Follett K.A., Bushnell D.L., et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. Am J Roentgenol 163 6 (1994) 1459-1465
71. Ortega-Lopez N., Mendoza-Vasquez R.G., Adame-Ocampo G., et al. [Validation of MRI and 18F-FDG-PET coregistration in patients with primary brain tumors]. Gac Med Mex 143 4 (2007) 309-316
72. Wong T.Z., van der Westhuizen G.J., and Coleman R.E. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12 4 (2002) 615-626
73. Pirotte B., Goldman S., Brucher J.M., et al. PET in stereotactic conditions increases the diagnostic yield of brain biopsy. Stereotact Funct Neurosurg 63 1-4 (1994) 144-149
74. Levivier M., Goldman S., Pirotte B., et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 82 3 (1995) 445-452
75. Goldman S., Levivier M., Pirotte B., et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38 9 (1997) 1459-1462
76. Massager N., David P., Goldman S., et al. Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg 93 6 (2000) 951-957
77. Jager P.L., Vaalburg W., Pruim J., et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 3 (2001) 432-445
78. Isselbacher K.J. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med 286 17 (1972) 929-933
79. Bergstrom M., Ericson K., Hagenfeldt L., et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 11 2 (1987) 208-213
80. Bergstrom M., Lundqvist H., Ericson K., et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 28 3 (1987) 225-229
81. Sato N., Suzuki M., Kuwata N., et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22 4 (1999) 210-214
82. Lilja A., Bergstrom K., Hartvig P., et al. Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. Am J Neuroradiol 6 4 (1985) 505-514
83. Derlon J.M., Bourdet C., Bustany P., et al. [11C]L-methionine uptake in gliomas. Neurosurgery 25 5 (1989) 720-728
84. O'Tuama L.A., Phillips P.C., Strauss L.C., et al. Two-phase [11C]L-methionine PET in childhood brain tumors. Pediatr Neurol 6 3 (1990) 163-170
85. Ogawa T., Shishido F., Kanno I., et al. Cerebral glioma: evaluation with methionine PET. Radiology 186 1 (1993) 45-53
86. Chung J.K., Kim Y.K., Kim S.K., et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29 2 (2002) 176-182
87. Herholz K., Holzer T., Bauer B., et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50 5 (1998) 1316-1322
88. Bergstrom M., Collins V.P., Ehrin E., et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7 6 (1983) 1062-1066
89. Mosskin M., Ericson K., Hindmarsh T., et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 30 3 (1989) 225-232
90. Pirotte B., Goldman S., David P., et al. Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. Acta Neurochir Suppl 68 (1997) 133-138
91. Kapouleas I., Alavi A., Alves W.M., et al. Registration of three-dimensional MR and PET images of the human brain without markers. Radiology 181 3 (1991) 731-739
92. Derlon J.M., Petit-Taboue M.C., Chapon F., et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 40 2 (1997) 276-287 [discussion: 87-8]
93. Mosskin M., Bergstrom M., Collins V.P., et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol Suppl 369 (1986) 157-160
94. Van Laere K., Ceyssens S., Van Calenbergh F., et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32 1 (2005) 39-51
95. De Witte O., Goldberg I., Wikler D., et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95 5 (2001) 746-750
96. Piepmeier J., Christopher S., Spencer D., et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38 5 (1996) 872-878 [discussion: 8-9]
97. Lote K., Egeland T., Hager B., et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 15 9 (1997) 3129-3140
98. Ribom D., Eriksson A., Hartman M., et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 92 6 (2001) 1541-1549
99. Ogawa T., Kanno I., Shishido F., et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32 3 (1991) 197-202
100. Lilja A., Lundqvist H., Olsson Y., et al. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 30 2 (1989) 121-128
101. Sonoda Y., Kumabe T., Takahashi T., et al. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 38 6 (1998) 342-347 [discussion: 7-8]
102. Levivier M., Wikier D., Goldman S., et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg 93 Suppl 3 (2000) 233-238
103. Levivier M., Wikler Jr. D., Massager N., et al. The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97 5 Suppl (2002) 542-550
104. Wienhard K., Herholz K., Coenen H.H., et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 32 7 (1991) 1338-1346
105. Pruim J., Willemsen A.T., Molenaar W.M., et al. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 197 1 (1995) 221-226
106. Kuwert T., Morgenroth C., Woesler B., et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 23 10 (1996) 1345-1353
107. Bader J.B., Samnick S., Moringlane J.R., et al. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 26 2 (1999) 144-151
108. Biersack H.J., Coenen H.H., Stocklin G., et al. Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. J Nucl Med 30 1 (1989) 110-112
109. Chen W., Silverman D.H., Delaloye S., et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47 6 (2006) 904-911
110. de Wolde H., Pruim J., Mastik M.F., et al. Proliferative activity in human brain tumors: comparison of histopathology and L-[1-(11)C]tyrosine PET. J Nucl Med 38 9 (1997) 1369-1374
111. Langen K.J., Jarosch M., Muhlensiepen H., et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 30 5 (2003) 501-508
112. Weber W.A., Wester H.J., Grosu A.L., et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27 5 (2000) 542-549
113. Floeth F.W., Pauleit D., Sabel M., et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48 4 (2007) 519-527
114. Floeth F.W., Sabel M., Stoffels G., et al. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 49 5 (2008) 730-737
115. Mehrkens J.H., Popperl G., Rachinger W., et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 88 1 (2008) 27-35
116. Langen K.J., Roosen N., Coenen H.H., et al. Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med 32 6 (1991) 1225-1229
117. Conti P.S. Introduction to imaging brain tumor metabolism with positron emission tomography (PET). Cancer Invest 13 2 (1995) 244-259
118. Grosu A.L., Weber W., Feldmann H.J., et al. First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 47 2 (2000) 517-526
119. Langen K.J., Ziemons K., Kiwit J.C., et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 38 4 (1997) 517-522
120. Shinoura N., Nishijima M., Hara T., et al. Brain tumors: detection with C-11 choline PET. Radiology 202 2 (1997) 497-503
121. Ohtani T., Kurihara H., Ishiuchi S., et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 28 11 (2001) 1664-1670
122. Hara T., Kosaka N., Shinoura N., et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 38 6 (1997) 842-847
123. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 6 (2005) 945-952
124. Choi S.J., Kim J.S., Kim J.H., et al. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32 6 (2005) 653-659
125. Saga T., Kawashima H., Araki N., et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 31 12 (2006) 774-780
126. Hatakeyama T., Kawai N., Nishiyama Y., et al. (11)C-methionine (MET) and (18)F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35 11 (2008) 2009-2017
127. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 11 (1998) 1334-1336
128. Hengstschlager M., Knofler M., Mullner E.W., et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 269 19 (1994) 13836-13842
129. Brown J.M., and Giaccia A.J. Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 65 1 (1994) 95-102
130. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 312 (1953) 638-648
131. Janssen H.L., Haustermans K.M., Balm A.J., et al. Hypoxia in head and neck cancer: how much, how important?. Head Neck 27 7 (2005) 622-638
132. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 19 (1996) 4509-4515
133. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 5 (1996) 941-943
134. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 2 (1997) 285-289
135. Evans S.M., Jenkins W.T., Joiner B., et al. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 56 2 (1996) 405-411
136. Koch C.J., Evans S.M., and Lord E.M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 72 4 (1995) 869-874
137. Ziemer L.S., Evans S.M., Kachur A.V., et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 30 2 (2003) 259-266